• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    eBook
    Top Features
    Lab Tested, Industry Approved: A Discussion of Ortho Device Testing & Analysis

    A Creative Spark Is Needed for Machining in Orthopedics

    Back Up: The 2023 Spine Technology Report

    Orthopedic Devices are Reaching a Digital Convergence

    Making Waves: Orthopedic Companies Breaking into the Market
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    ODT's Most-Read Stories This Week—Sept. 23

    Anika Releases RevoMotion Reverse Shoulder Arthroplasty System

    Exactech's Activit-E Polyethylene OK'ed for Vantage Total Ankle

    Tyber Nets Several Regulatory Nods for K-Wires, Steinmann Pins

    Relievant Medsystems Releases Medability-Powered Intracept Simulator
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    ODT's Most-Read Stories This Week—Sept. 23

    ODT's Most-Read Stories This Week—Sept. 16

    Discover Secrets for Fast Tracking Your Device’s Path to Market

    Lab Tested, Industry Approved: A Discussion of Ortho Device Testing & Analysis

    A Creative Spark Is Needed for Machining in Orthopedics
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Revolutionizing ACL Restoration

    Exploring Issues Surrounding Quality Control & Device Design for Osteoporosis Testing & Monitoring

    How to Build a More Resilient Orthopedic Supply Chain

    Meeting the Challenges of the Medical Device Industry with Compact Manufacturing Innovation

    Managing Risk in the Age of Rising Orthopedic Automation
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Komet Medical - Gebr. Brasseler GmbH & Co. KG

    Gauthier Biomedical Inc.

    Tiodize

    Oberg Medical

    Five Star Companies Inc.
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • eBook
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    The Case for Using Historical Control in Clinical Trial Design

    Historical control refers to the use of data from past studies to estimate potential response to a placebo or standard care treatment among trial patients.

    The Case for Using Historical Control in Clinical Trial Design
    Michael Coladonato and Lucas Tatem, MCRA08.12.22
    A prospective, randomized controlled trial (RCT) is the gold standard and the U.S. Food and Drug Administration’s (FDA) preferred study design because it provides the highest level of scientific evidence.

    Prospective RCTs generate robust and reliable evidence through bias minimization (randomizing subjects to investigational or control groups), variability control (through carefully constructed eligibility criteria), and stringent data collection requirements (in accordance with a pre-defined protocol). A study’s randomization also ensures that populations are well matched by balancing subject characteristics (both observed and unobserved).1 In premarket studies, the RCT design is used to evaluate new interventions or treatments seeking Premarket Approval (PMA) and/or New Drug Application (NDA) consent from the FDA. PMAs compare the investigational product to an active control cohort, while NDAs traditionally evaluate the investigational product against a placebo. While the RCT study design is considered the benchmark, this approach can be impractical or excessively challenging to conduct due to the lack of viable treatment alternatives or unethical randomization of trial subjects.

    When a prospective RCT is not possible or considered overly burdensome to clinicians and/or patients, alternative trial designs can be utilized. One alternative solution involves substituting an active concurrent control with a viable historical control. Using a historical control requires a robust justification and early involvement with the FDA via pre-submissions or Type C meetings. There is regulatory precedence to support applying historical controls to partially or fully replace a concurrent control2 but organizations should be aware of the pros and cons of such a technique before making the switch.

    Historical control refers to the practice of using data from past studies and administrative databases to estimate potential response(s) to a placebo or standard care treatment among trial patients. When considering historical evidence in clinical trial design and data analysis planning, many factors must be considered. Ultimately, the historical control data characteristics should closely align with the characteristics of the study’s investigational arm. Historical data may be obtained from various sources as long as the data is relevant and reliable. Data reliability and relevancy are necessary to generate valid scientific evidence for regulatory decisions.

    Real-world data (RWD) is one of the primary resources for constructing historical control datasets, and include patient registries, medical charts, and systematic reviews of published clinical data. Regardless of the source, it is imperative to accurately and reliably capture RWD at clinically relevant time intervals in order to meet the FDA’s threshold for RWE (real-world evidence) and serve as a benchmark for providing a reasonable assurance of safety and efficacy compared to the investigational product.

    Since RWD can be obtained from different sources with varied structures and quality, many factors must be taken into account when assessing the viability of leveraging data as a historical control. Several important considerations include propensity score matching, performance outcomes, available sample size, and available follow-up time intervals. Propensity score matching attempts to reduce treatment assignment bias and mimic randomization by creating an investigational treatment subject sample and comparing it (with all observed and unobserved covariates) to patients receiving a placebo or standard treatment. Performance outcomes for the historical control should align with the proposed investigational arm and should provide data on both safety and effectiveness of the target population. The historical control’s sample size must be sufficient to power the statistical analysis and should be representative of the target population. Lastly, follow-up time and visit intervals should be relevant and aligned with the investigational arm. When historical information is leveraged appropriately, the evidence generated can be used to support regulatory decision-making and provide a least burdensome regulatory path to market.

    It is very important to develop a thorough analytical plan before accessing, retrieving, and analyzing RWD for a historical control so that source and selection bias—as well as post-hoc analyses—are minimized. Further, the study protocol and statistical analysis plan (SAP) should address the same elements a traditional clinical trial protocol and SAP would cover.2 Additionally, sponsors should consider the availability of patient-level data, including source statistics, when selecting RWD; information ideally should be provided in the required standardized file formats and data structures in accordance with statutory standardized variables and/or definitions, when applicable. The FDA recently published several relevant resources specifically related to the use of RWD in investigational new drug applications, including the draft guidance documents “Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry,” and “Data Standards for Drug and Biological Product Submissions Containing Real-World Data: Draft Guidance for Industry.”

    Using a historical control arm instead of enrolling an active comparator can help reduce or eliminate the need for control patient enrollment and shorten clinical study periods, which ultimately can help cut the costs of generating the required evidence to support product approvals. Additional time and cost-reducing factors include less overhead for investigational sites and easier enrollment of the single-arm investigational study due to clear treatment assignment.

    Historical control data may be leveraged as part of various regulatory activities to support the benefit-risk profile of devices at various points in their life cycle. This includes but is not limited to expanded indications for use (e.g., through powered subgroup analyses of registry data), post-market surveillance studies, post-approval device surveillance, and supplemental data. With each use of historical data, there are nuanced factors that must be considered to ensure valid scientific evidence is generated from RWD and the data substantiates the justification of this alternate path.

    The use of historical data, including RWD to generate RWE in support of a regulatory decision, can be a daunting task. But expertise from organizations like MCRA can help ease the difficulties associated with such an approach to clinical trials. Leveraging RWD, applying appropriate risk management strategies, and mitigating sources of bias effectively to generate valid scientific evidence can provide the least burdensome path to market. And that’s certainly a path worth taking. 

    References
    1. Hariton, E., & Locascio, J. J. (2018). Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG : an international journal of obstetrics and gynaecology, 125(13), 1716. https://doi.org/10.1111/1471-0528.15199
    2. Ghadessi, M., Tang, R., Zhou, J., Liu, R., Wang, C., Toyoizumi, K., ... & Beckman, R. A. (2020). A roadmap to using historical controls in clinical trials–by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet Journal of Rare Diseases, 15(1), 1-19.


    Michael Coladonato is a senior associate, regulatory affairs, at MCRA LLC with four years of experience in medical device regulation. At MCRA, Michael provides guidance on regulatory strategies and submissions across various therapies including spine, orthopedics, wound care, and cardiovascular, as well as drugs, and biologics. Michael has a wide range of regulatory submission experience including but not limited to IDEs, INDs, PMAs, 510(k)s, HUDs, De Novos, Breakthrough Device Designations, and Clinical Evaluation Reports. Michael leads and supports numerous projects from regulatory strategy assessments through full submission writing and communications with FDA. Michael earned his bachelor’s degree in biomedical engineering from The Catholic University of America.

    Lucas Tatem, M.Eng., is a regulatory affairs associate at MCRA, where he is primarily focused on supporting and advising clients in the completion of various regulatory submissions specifically for spine and orthopedic implants, as well as wound care products. Lucas has supported projects including 510(k)s,  pre-submissions, Premarket Approval (PMAs), Investigational Device Exemptions, Investigational New Drug applications and European Clinical Evaluation Report submissions. He attended Clemson University and earned a master’s degree in biomedical engineering with a concentration in biomaterials.
      Loading, Please Wait..

      Breaking News
      • ODT's Most-Read Stories This Week—Sept. 23
      • Anika Releases RevoMotion Reverse Shoulder Arthroplasty System
      • Exactech's Activit-E Polyethylene OK'ed for Vantage Total Ankle
      • Tyber Nets Several Regulatory Nods for K-Wires, Steinmann Pins
      • Relievant Medsystems Releases Medability-Powered Intracept Simulator
      View Breaking News >
      CURRENT ISSUE

      September/October 2023

      • A Discussion of Ortho Device Testing & Analysis
      • A Creative Spark Is Needed for Machining in Orthopedics
      • Back Up: The 2023 Spine Technology Report
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Releases Sustainability Report for Omega-3s Industry
      ABC’s Journal HerbalGram Celebrates 40th Anniversary
      Curcumin May Be As Effective as PPI for Indigestion
      Coatings World

      Latest Breaking News From Coatings World

      ACS Reports Chameleon Inspired Building Coating
      Substrate Wetting Agent Available from BRB International
      Nouryon Manufacturing Network Transitions to 100% Electricity From Renewable Sources in Brazil
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—Sept. 23
      Beckman Coulter Helping Labs Comply With Annex 1 Regulation
      FDA Clears MeMed BV Direct From Whole Blood
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Eftilagimod Cleared for Clinical Trial Use in the UK
      Veranova Names William Sanders Global VP of Chemical Development Ops
      Chime, Panolos Partner to Advance Multi-specific Therapeutic Proteins
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Hailey Bieber's Rhode Expands Into Makeup
      Avon Enters Retail Partnership with Superdrug
      IT Award Winners Announced at MakeUp in NY
      Happi

      Latest Breaking News From Happi

      Dental Care Trends and SBLA Beauty's Advertising Claims Under Scrutiny
      OffCourt Debuts in Walmart Stores Nationwide
      Gen Z Is Sweet On Smelling Good
      Ink World

      Latest Breaking News From Ink World

      Cooper Watson Acquires Tower Products
      The Durst Group Awarded Eight 2023 PRINTING United Alliance Pinnacle Awards
      Weekly Recap: Wikoff Color, HP, INX VC Top This Week’s Stories
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      PRX Market debuts, Tower Products acquired and more
      Flexo Wash to exhibit at FTA Fall Technical Conference
      Recyclable, deinkable stand-up pouch wins Gold in Germany
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Soft N' Dry Seeks to Expand Private Label Roll Out, Albis Completes Work on Line
      Lenzing Earns EU Ecolabel at Indonesian Plant
      Albis Completes Work On Extra Wide Carding, Blending Line
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—Sept. 23
      Anika Releases RevoMotion Reverse Shoulder Arthroplasty System
      Exactech's Activit-E Polyethylene OK'ed for Vantage Total Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      HID to Showcase Future-Proof Solutions at GITEX 2023
      Weekly Recap: Mergers and Acquisitions, IEC’s IME Standards Top This Week’s Stories
      EU-Funded Collaboration Hub Aims to Mainstream Printed Electronics

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login